Healthcare / Medical Instruments & SuppliesKuala Lumpur
$0.07
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-18.3M · quality 57.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$110M
P/E
N/A
•EV/EBITDA
22.1x
↑ROE
1.8%
↑Gross Margin
24.8%
↓Debt/Equity
0.52
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-23.8%
FCF CAGR
—
FCF margin
-38.5%
FCF / Net income
-5.62x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $47.4M · net income $3.2M · FCF $-18.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $47.4M | $47.4M | $50.3M | $86.8M | $107.1M |
| Net Income | $3.2M | $3.2M | $-117.1M | $-24.7M | $9.6M |
| EBITDA | $8.3M | $8.3M | $-101.0M | $-12.8M | $20.0M |
| EPS | — | — | -0.16 | -0.04 | 0.02 |
| Gross Margin | 24.8% | 24.8% | -17.4% | -7.5% | 25.9% |
| Operating Margin | -1.6% | -1.6% | -225.0% | -28.5% | 13.0% |
| Net Margin | 6.9% | 6.9% | -232.7% | -28.4% | 9.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.52 | 0.52 | 0.55 | 0.57 | 0.49 |
| Current Ratio | 2.28 | 2.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-18.3M | $-18.3M | $-34.3M | $-9.4M | $-40.3M |
| Returns | |||||
| ROE | 1.8% | 1.8% | -65.8% | -14.0% | 4.8% |
| Valuation | |||||
| P/E | — | — | — | — | 12.86 |
| EV/EBITDA | 22.06 | 22.06 | — | — | 10.01 |
| P/B | 0.60 | 0.60 | 0.37 | 0.45 | 0.62 |
| Growth & Yield | |||||
| Revenue Growth | -5.9% | -5.9% | -42.0% | -18.9% | — |
| EPS Growth | — | — | -268.7% | -308.6% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-23.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.16 → n/d
Residual
-23.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.